Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma
- 1 January 2007
- journal article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 12 (1) , 107-113
- https://doi.org/10.1634/theoncologist.12-1-107
Abstract
Learning Objectives: After completing this course, the reader will be able to: Discuss the mechanism of action of the newly approved targeted cancer drug sunitinib.List the current approved oncology indications for this agent.Describe the pharmacology, metabolism, and side effect profile of sunitinib. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.comKeywords
This publication has 7 references indexed in Scilit:
- Renal-Cell CarcinomaNew England Journal of Medicine, 2005
- Interleukin-2 in the Treatment of Renal Cell Carcinoma and Malignant MelanomaPublished by Springer Nature ,2005
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosisVirchows Archiv, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Adrenal Dysfunction in Hemodynamically Unstable Patients in the Emergency DepartmentAcademic Emergency Medicine, 1999